Risk Minimization Measures for Blood Screening HIV-1 Nucleic Acid Amplification Technique Assays in Germany | Zendy

Michael Chudy | Zendy; Julia Kreß | Zendy; Jochen Halbauer | Zendy; M. Heiden | Zendy; Markus B. Funk | Zendy; C. Micha Nübling | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Risk Minimization Measures for Blood Screening HIV-1 Nucleic Acid Amplification Technique Assays in Germany

Author(s) -

Michael Chudy,

Julia Kreß,

Jochen Halbauer,

M. Heiden,

Markus B. Funk,

C. Micha Nübling

Publication year - 2013

Publication title -

transfusion medicine and hemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.971

H-Index - 39

eISSN - 1660-3818

pISSN - 1660-3796

DOI - 10.1159/000357103

Subject(s) - nat , nucleic acid , virology , biology , human immunodeficiency virus (hiv) , viral load , nucleic acid test , computational biology , whole blood , genetics , immunology , medicine , disease , infectious disease (medical specialty) , covid-19 , computer network , pathology , computer science

Several publications describe HIV-1 RNA false-negative results or viral load underquantitation associated with Communauté Européenne(CE)-marked qualitative or quantitative nucleic acid amplification technique (NAT) assays. 6 cases occurred during blood screening in Germany, with 2 of them causing HIV-1 transmissions to recipients of blood components. The implicated NAT assays were mono-target assays amplifying in different viral genome regions (gag or long terminal repeat).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research